Aptahem AB (publ) (NGM:APTA)

Sweden · Delayed Price · Currency is SEK

0.802

-0.094 (-10.49%)

At close: Feb 27, 2026

1.52% (1Y)

Market Cap	16.82M
Revenue (ttm)	2.59M
Net Income (ttm)	-6.49M
Shares Out	20.97M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,164
Average Volume	28,504
Open	0.878
Previous Close	0.896
Day's Range	0.802 - 0.878
52-Week Range	0.560 - 2.400
Beta	0.44
RSI	38.44
Earnings Date	Feb 12, 2026

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 3

Stock Exchange Nordic Growth Market

Ticker Symbol APTA

Full Company Profile

Financial Performance

In 2025, Aptahem AB's revenue was 2.59 million, a decrease of -31.47% compared to the previous year's 3.77 million. Losses were -6.49 million, -24.26% less than in 2024.

Financial Statements

News

There is no news available yet.